Emmanuelle DiTomaso
Beth Israel Deaconess Medical Center(US)Bayer (United States)(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Glioma Diagnosis and Treatment, Radiomics and Machine Learning in Medical Imaging
Most-Cited Works
- → Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation(2003)835 cited
- → Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinases(2004)678 cited
- → Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer(2020)153 cited
- → Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2(2009)74 cited
- → Pten Loss in Olig2 Expressing Neural Progenitor Cells and Oligodendrocytes Leads to Interneuron Dysplasia and Leukodystrophy(2013)28 cited
- → Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).(2013)5 cited
- → Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy(2017)5 cited
- → PD09-03: Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy.(2011)5 cited
- → Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4(2013)3 cited
- → Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.(2018)3 cited